CD61, Blocking Peptide

GP3A; Integrin beta-3; Platelet membrane glycoprotein IIIa; GPIIIa; CD61

For Research Use Only. Not for use in diagnostic procedures.

Synthetic

>85%

Lyophilized Powder

Shipped at 4 degree C. Store at -20 degree C for one year.

Small volumes of ITGB3 blocking peptide vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The peptide is used to block Anti-CD61 reactivity.

Blocking (BL)

Blocking Peptide to the diluted primary antibody in a molar ratio of 10:1 (peptide to antibody) and incubate the mixture at 4 degree C for overnight or at room temperature for 2 hours.

86,694 Da

integrin subunit beta 3

integrin beta-3

Integrin beta-3

GP3A; GPIIIa  [Similar Products]

ITB3_HUMAN

The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008]

ITGB3: integrin alpha-V/beta-3 is a receptor for cytotactin, fibronectin, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin, vitronectin and von Willebrand factor. Integrin alpha-IIB/beta-3 is a receptor for fibronectin, fibrinogen, plasminogen, prothrombin, thrombospondin and vitronectin. Integrins alpha-IIB/beta-3 and alpha-V/beta-3 recognize the sequence R-G-D in a wide array of ligands. Integrin alpha-IIB/beta-3 recognizes the sequence H-H-L-G-G-G-A-K-Q-A-G-D-V in fibrinogen gamma chain. Following activation integrin alpha- IIB/beta-3 brings about platelet/platelet interaction through binding of soluble fibrinogen. This step leads to rapid platelet aggregation which physically plugs ruptured endothelial surface.

Protein type: Cell adhesion; Membrane protein, integral; Motility/polarity/chemotaxis

Chromosomal Location of Human Ortholog: 17q21.32

Cellular Component: cell surface; filopodium membrane; focal adhesion; integral to plasma membrane; integrin complex; melanosome; microvillus membrane; nucleus; plasma membrane; platelet alpha granule membrane; receptor complex

Molecular Function: cell adhesion molecule binding; enzyme binding; extracellular matrix binding; fibronectin binding; identical protein binding; platelet-derived growth factor receptor binding; protease binding; protein binding; protein disulfide isomerase activity; vascular endothelial growth factor receptor 2 binding; viral receptor activity

Biological Process: activation of protein kinase activity; angiogenesis involved in wound healing; axon guidance; blood coagulation; cell adhesion; cell growth; cell migration; cell-matrix adhesion; cell-substrate adhesion; cell-substrate junction assembly; entry of virus into host cell; extracellular matrix organization and biogenesis; heterotypic cell-cell adhesion; integrin-mediated signaling pathway; leukocyte migration; mesodermal cell differentiation; negative chemotaxis; negative regulation of lipid transport; negative regulation of lipoprotein metabolic process; negative regulation of low-density lipoprotein receptor biosynthetic process; platelet activation; platelet degranulation; positive regulation of endothelial cell proliferation; positive regulation of peptidyl-tyrosine phosphorylation; positive regulation of protein amino acid phosphorylation; positive regulation of vascular endothelial growth factor receptor signaling pathway; protein folding; regulation of bone resorption; smooth muscle cell migration; tube development; vascular endothelial growth factor receptor signaling pathway; wound healing

Disease: Bleeding Disorder, Platelet-type, 16; Glanzmann Thrombasthenia; Myocardial Infarction, Susceptibility To

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.